Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Oct. 31, 2014 | Dec. 09, 2014 | |
Document And Entity Information | ||
Entity Registrant Name | Neurokine Pharmaceuticals Inc. | |
Entity Central Index Key | 1464165 | |
Document Type | 10-Q | |
Document Period End Date | 31-Oct-14 | |
Amendment Flag | FALSE | |
Current Fiscal Year End Date | -30 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 115,767,073 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2015 |
Balance_Sheets
Balance Sheets (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
Current Assets: | ||
Cash | 1,370 | 1,044 |
Other receivable | 6,000 | 5,251 |
Total current assets | 7,370 | 6,295 |
Property and equipment (Note 3) | 531 | 872 |
Total Assets | 7,901 | 7,167 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 44,693 | 35,373 |
Loans payable (Note 4) | 71,049 | 55,306 |
Due to related parties (Note 10) | 190,735 | 151,384 |
Convertible debentures and related accrued interest, net of unamortized discount of $nil and $7,304, respectively (Note 5) | 321,881 | 286,852 |
Derivative liabilities (Note 6) | 150,473 | 228,765 |
Total liabilities | 778,831 | 757,680 |
Stockholders' Deficit | ||
Common stock: Unlimited shares authorized, without par value,115,767,073 and 100,767,073 shares issued and outstanding, respectively | 1,274,148 | 1,184,148 |
Common stock issuable (Note 7) | 225,000 | 225,000 |
Additional paid-in capital | 757,586 | 754,586 |
Accumulated deficit | -3,027,664 | -2,914,247 |
Total stockholder's deficit | -770,930 | -750,513 |
Total liabilities and stockholder's deficit | 7,901 | 7,167 |
Balance_Sheets_Parenthetical
Balance Sheets (Parenthetical) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
Balance Sheets Parenthetical | ||
Convertible debentures, net of unamortized discount | 7,304 | |
Common stock, Shares authorized | ||
Common stock, Shares issued | 115,767,073 | 100,767,073 |
Common stock, Shares outstanding | 115,767,073 | 100,767,073 |
Statements_of_Operations
Statements of Operations (CAD) | 3 Months Ended | 9 Months Ended | ||
Oct. 31, 2014 | Oct. 31, 2013 | Oct. 31, 2014 | Oct. 31, 2013 | |
Statements Of Operations | ||||
Revenue | ||||
EXPENSES | ||||
Amortization | 114 | 113 | 341 | 342 |
Foreign exchange (loss) gain | 10,864 | 4,014 | 7,726 | 11,399 |
General and administrative | 14,077 | 5,017 | 31,355 | 19,967 |
Management fees (Note 10) | 7,500 | 3,000 | 22,500 | |
Professional fees | 2,468 | 4,437 | 23,266 | 12,934 |
Total expenses | 27,523 | 21,081 | 65,688 | 67,142 |
Loss from operations | -27,523 | -21,081 | -65,688 | -67,142 |
Other income (expense) | ||||
Accretion of discount on convertible debentures | -2,235 | -7,304 | -3,451 | |
Financing costs | -90,000 | -63,000 | ||
Gain (loss) on change in fair value of derivative liabilities | -130,089 | -79,170 | 78,294 | -49,403 |
Loss on settlement of debt | -490,000 | -490,000 | ||
Interest expense | -10,109 | -9,047 | -28,719 | -25,755 |
Total other income (expense) | -140,198 | -580,452 | -47,729 | -631,609 |
Net loss | -167,721 | -601,533 | -113,417 | -698,751 |
Net loss per share, basic and diluted | -0.01 | -0.02 | ||
Weighted average shares outstanding - basic and diluted | 115,767,073 | 49,843,160 | 110,074,004 | 40,510,663 |
Statements_of_Cash_Flows
Statements of Cash Flows (CAD) | 9 Months Ended | |
Oct. 31, 2014 | Oct. 31, 2013 | |
Statements Of Cash Flows | ||
Net loss | -113,417 | -698,751 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Accretion of discount on convertible debentures | 7,304 | 3,451 |
Amortization | 341 | 342 |
(Gain) loss on change in fair value of derivative liabilities | -78,292 | 49,403 |
Stock issued for financing costs | 90,000 | |
Stock issued for loan default | 63,000 | |
Loss on settlement of debt | 490,000 | |
Services contributed by officer | 3,000 | |
Changes in operating assets and liabilities: | ||
Other receivable | -749 | -756 |
Accounts payable and accrued liabilities | 45,288 | 20,256 |
Due to related parties | 39,351 | 46,688 |
Net cash provided by (used in) operating activities | -7,174 | -26,367 |
Financing activities | ||
Proceeds from loan payable | 7,500 | 10,000 |
Proceeds from issuance of convertible debentures | 15,000 | |
Net cash provided by financing activities | 7,500 | 25,000 |
Effect of foreign exchange | 9,214 | |
Increase in cash | 326 | 7,847 |
Cash - beginning of period | 1,044 | 475 |
Cash - end of period | 1,370 | 8,322 |
Supplemental disclosures: | ||
Interest paid | ||
Income tax paid | ||
Non-cash investing and financing activities: | ||
Shares issued for settlement of debt | 525,000 |
Nature_of_Operations_and_Conti
Nature of Operations and Continuance of Business | 9 Months Ended |
Oct. 31, 2014 | |
Notes to Financial Statements | |
Nature of Operations and Continuance of Business | Neurokine Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. The Company is in the business of developing and commercializing new uses for existing prescription drugs for diseases mediated by acute and chronic inflammatory reactions as well as developing proprietary encapsulation technology in the treatment of neurodegenerative diseases. |
These financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at October 31, 2014, the Company has not earned any revenue, has a working capital deficit of $771,461 and an accumulated deficit of $3,027,664. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company be unable to continue as a going concern. |
Significant_Accounting_Policie
Significant Accounting Policies | 9 Months Ended | |
Oct. 31, 2014 | ||
Notes to Financial Statements | ||
Significant Accounting Policies | (a) | Basis of Presentation |
The financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in Canadian dollars. The Company’s fiscal year-end is January 31. | ||
(b) | Use of Estimates | |
The financial statements and the related notes of the Company are prepared in accordance with generally accepted evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, valuation of convertible debentures, assumptions used to determine the fair values of stock-based compensation and derivative liabilities, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | ||
(c) | Interim Financial Statements | |
These interim unaudited financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. | ||
(d) | Cash and Cash Equivalents | |
The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at October 31 and January 31, 2014, the Company had no cash equivalents. | ||
(e) | Property and Equipment | |
Property and equipment is comprised of office equipment and is recorded at cost. The Company amortizes the cost of equipment on a straight-line basis over their estimated useful life of five years. | ||
(f) | Long-lived Assets | |
In accordance with ASC 360, “Property, Plant and Equipment”, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. | ||
(g) | Stock-Based Compensation | |
The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock-Based Compensation, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. | ||
(h) | Derivative Financial Instruments | |
Derivative financial instruments that are not classified as equity and are not used in hedging relationships are measured at fair value. Subsequent changes to fair value are recorded in the statement of operations. | ||
(i) | Loss Per Share | |
The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2014, the Company has 4,599,844 (January 31, 2014 – 27,142,888) potentially dilutive shares. | ||
(j) | Comprehensive Loss | |
ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at October 31 and January 31, 2014, the Company had no items representing comprehensive income or loss. | ||
(k) | Research and Development Costs | |
Research costs are expensed in the period that they are incurred. | ||
(l) | Financial Instruments and Fair Value Measures | |
ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: | ||
Level 1 | ||
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. | ||
Level 2 | ||
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. | ||
Level 3 | ||
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. | ||
(m) | Foreign Currency Translation | |
The Company’s functional currency and its reporting currency is the Canadian dollar and foreign currency transactions are primarily undertaken in United States dollars. Monetary assets and liabilities are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Expenses are translated at average rates for the period. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. | ||
(n) | Recent Accounting Pronouncements | |
In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development or exploration stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of October 31, 2014. | ||
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. | ||
(o) | Comparative Figures | |
During the period, the Company determined that certain transactions affecting stockholders’ equity had inadvertently been recorded using a par value of $0.001 in the fiscal year ended January 31, 2014. | ||
The Company has determined that its previously filed Form 10-K included a misclassification of $33,000 related to equity. After taking the reclassification into account, the balances of common shares and additional paid-in capital as of January 31, 2014, are $1,184,148 and $754,586, respectively. |
Property_and_Equipment
Property and Equipment | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Notes to Financial Statements | |||||||||||||||||
Property and Equipment | Cost | Accumulated amortization | October 31, 2014 Net carrying value | January 31, 2014 Net carrying value | |||||||||||||
$ | $ | $ | $ | ||||||||||||||
Office furniture and equipment | 2,276 | 1,745 | 531 | 872 | |||||||||||||
Loans_Payable
Loans Payable | 9 Months Ended | |
Oct. 31, 2014 | ||
Notes to Financial Statements | ||
Loans Payable | (a) | On March 30, 2012, the Company issued a promissory note to a non-related party for $30,000. The loan is unsecured, bears interest at 24% per annum, and was due on March 30, 2013. As at October 31, this loan remains outstanding. |
(b) | On September 19, 2013, the Company issued a promissory note to a non-related party for US$10,000. The loan is unsecured, bears interest at 24% per annum, and was due on September 18, 2014. As at October 31, 2014, this loan remains outstanding. | |
(c) | On June 27, 2014, the Company issued a promissory note to a non-related party of the Company for $7,500. The loan is unsecured, bears interest at 24% per annum, and is due on June 27, 2015. |
Convertible_Debentures
Convertible Debentures | 9 Months Ended | |
Oct. 31, 2014 | ||
Notes to Financial Statements | ||
Convertible Debentures | (a) | On December 17, 2010, the Company issued a convertible debenture with a non-related party for $65,079 (US$65,000). The debenture is unsecured, bears interest at 8% per annum, and matured on September 17, 2011. The note is convertible into common shares at a conversion price equal to 55% of the average closing market price of the lowest three trading prices of the Company’s common stock during the preceding ten days prior to conversion. The Company recorded the conversion feature of the convertible debenture as a derivative liability at an estimated fair value of $65,079 with a corresponding discount to the convertible debenture. On June 23, 2011, the Company issued 145,455 common shares to convert $11,674 (US$12,000). On June 29, 2011, the Company issued 169,697 common shares to convert $13,792 (US$14,000). As of October 31, 2014, the carrying value of the convertible debenture is $22,542 (US$20,000) (January 31, 2014 - $22,276 (US$20,000)), plus the accrued default penalty of $11,271 (US$10,000) (January 31, 2014 - $11,138 (US$10,000)) and accrued interest of $1,572 (US$1,395) (January 31, 2014 - $1,553 (US$1,395)). As of October 31, 2014, the fair value of the conversion option derivative liability was $81,684 (January 31, 2014 - $126,868). |
(b) | On February 23, 2011, the Company issued a convertible debenture with a non-related party for $37,944 (US$40,000). The debenture is unsecured, bears interest at 8% per annum, and matured on December 23, 2011. The note is convertible into common shares at a conversion price equal to 55% of the average closing market price of the lowest three trading prices of the Company’s common stock during the preceding ten days prior to conversion. The Company recorded the conversion feature of the convertible debenture as a derivative liability at an estimated fair value of $37,944 with a corresponding discount to the convertible debenture. On July 11, 2011, the Company issued 230,303 common shares to convert $18,270 (US$19,000). As of October 31, 2014, the carrying value of the convertible debenture is $45,084 (US$40,000) (January 31, 2014 - $44,552 (US$40,000)), plus the accrued default penalty of $22,542 (US$20,000) (January 31, 2014 – $22,276 (US$20,000)) and accrued interest of $4,400 (US$3,904) (January 31, 2014 - $4,348 (US$3,904)). As of October 31, 2014, the fair value of the conversion option derivative liability was $47,087 (January 31, 2014 - $73,133). | |
(c) | On July 4, 2011, the Company issued a note payable with a non-related party for $85,000. The note was unsecured, due interest at 24% per annum, and due on October 4, 2011. On October 4, 2011, the note was extended to January 4, 2012 under the same terms of the original agreement. | |
On December 4, 2011, the Company agreed to modify the principal balance owing of $85,000 and accrued interest of $8,551 into a new $100,000 note payable, which is unsecured, due interest at 24% per annum, and due on December 3, 2012. In addition, the note became convertible into common shares of the Company at a conversion rate of $0.001 per share. As part of the conversion to extend the note, the Company issued 10,000,000 common shares with a fair value of $225,000 as a termination fee of the original note agreement. | ||
As the modified debt terms include a beneficial conversion feature, the Company accounted for the modified debt terms in accordance with ASC 470, Debt – Debt with Conversions and Other Options. The conversion feature resulted in a discount on the convertible note of $100,000. As of October 31, 2014, the carrying value of the convertible debenture is $112,710 (US$100,000) (January 31, 2014 - $111,380 (US$100,000)), plus accrued interest of $78,706 (US$69,830) (January 31, 2014 - $57,783 (US$51,879)). | ||
(d) | On April 26, 2013, the Company issued a convertible debenture with a non-related party for $15,254 (US$15,000). The debenture is secured by 15,000,000 shares of common stock of the Company, to be delivered to the lender if principal and interest are not repaid on maturity, bears interest at 24% per annum, and matures on April 27, 2014. The note, plus accrued interest, is convertible into common shares at a conversion price of US$0.001 per share at the discretion of the lender and at any time during the term of this debenture. | |
As the convertible debt terms include a beneficial conversion feature, the Company accounted for the debt terms in accordance with ASC 470, Debt – Debt with Conversions and Other Options. The conversion feature resulted in a discount on the convertible note of $15,000. During the nine months ended October 31, 2014, the Company recorded accretion expense of $7,304 (2013 - $1,216). As of October 31, 2014, the carrying value of the convertible debenture is $16,907 (US$15,000) (January 31, 2014 - $8,572 (US$7,696)), plus accrued interest of $6,147 (US$5,454) (January 31, 2014 - $2,974 (US$2,670)). |
Derivative_Liabilities
Derivative Liabilities | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Notes to Financial Statements | |||||||||||||||||
Derivative Liabilities | Derivative liabilities consist of convertible debentures with variable conversion prices and share purchase warrants originally issued in private placements with conversion/exercise prices denominated in United States dollars, which differs from the Company’s functional currency. The fair values of these derivative liabilities are as follows: | ||||||||||||||||
31-Oct-14 | 31-Jan-14 | ||||||||||||||||
$ | $ | ||||||||||||||||
(unaudited) | |||||||||||||||||
December 2010 convertible debenture | 52,698 | 81,848 | |||||||||||||||
February 2011 convertible debenture | 28,376 | 44,072 | |||||||||||||||
Default penalty on convertible debentures | 47,697 | 74,080 | |||||||||||||||
75,000 warrants expiring on July 4, 2013 | – | – | |||||||||||||||
3,800,000 warrants expiring on July 30, 2015 | 21,702 | 28,765 | |||||||||||||||
150,473 | 228,765 | ||||||||||||||||
The fair values of derivative financial liabilities were determined using the Black-Scholes option pricing model, using the following assumptions: | |||||||||||||||||
Expected | Risk-free | Expected | Expected Life | ||||||||||||||
Volatility | Interest Rate | Dividend Yield | (in years) | ||||||||||||||
As at issuance date: | |||||||||||||||||
December 2010 convertible debenture | 125 | % | 1.19 | % | 0 | % | 0.75 | ||||||||||
February 2011 convertible debenture | 125 | % | 1.27 | % | 0 | % | 0.75 | ||||||||||
Default penalty on convertible debenture | 125 | % | 0.08 | % | 0 | % | 0.5 | ||||||||||
75,000 warrants expiring on July 4, 2013 | 125 | % | 0.3 | % | 0 | % | 2 | ||||||||||
3,800,000 warrants expiring on July 30, 2015 | 125 | % | 1.26 | % | 0 | % | 4.5 | ||||||||||
As at October 31, 2014: | |||||||||||||||||
December 2010 convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
February 2011 convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
Default penalty on convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
3,800,000 warrants expiring on July 30, 2015 | 240 | % | 0.08 | % | 0 | % | 0.75 |
Common_Shares
Common Shares | 9 Months Ended |
Oct. 31, 2014 | |
Notes to Financial Statements | |
Common Shares | On March 24, 2013, 30,000,000 shares of common stock were issuable pursuant to a default penalty on a convertible note payable. |
On April 27, 2014, 15,000,000 shares of common stock were issuable pursuant to a default penalty on a convertible note payable. $90,000 was recorded as financing costs on the Statement of Operations for the nine months ended October 31, 2014 related to this default (October 31, 2013 - $63,000). | |
On September 24, 2013, the Company issued 35,000,000 shares of common stock to settle $35,000 of due to related party. |
Share_Purchase_Warrants
Share Purchase Warrants | 9 Months Ended | ||||||||||
Oct. 31, 2014 | |||||||||||
Notes to Financial Statements | |||||||||||
Share Purchase Warrants | The following table summarizes the continuity of share purchase warrants: | ||||||||||
Number of Warrants | Weighted Average Exercise Price (US$) | ||||||||||
Balance, January 31, 2013 | 3,875,000 | 0.01 | |||||||||
Expired | (75,000 | ) | 0.15 | ||||||||
Balance, October 31 and January 31, 2014 | 3,800,000 | 0.01 | |||||||||
As at October 31, 2014, the following share purchase warrants were outstanding: | |||||||||||
Number of Warrants | Exercise Price $ | Grant Date | Expiry Date | ||||||||
3,800,000 | 0.005 | 30-Jul-10 | 30-Jul-15 | ||||||||
Stock_Options
Stock Options | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Notes to Financial Statements | |||||||||||||||||
Stock Options | The following table summarizes the continuity of the Company’s stock options: | ||||||||||||||||
Number of Options | Weighted Average Exercise Price(US$) | Weighted Average Remaining Contractual Life (years) | Aggregate Intrinsic Value (US$) | ||||||||||||||
Outstanding and exercisable, January 31, 2013 | 800,000 | 0.005 | 2.3 | – | |||||||||||||
Outstanding and exercisable, January 31, 2014 | 800,000 | 0.005 | 1.3 | – | |||||||||||||
Outstanding and exercisable, October 31, 2014 | 800,000 | 0.005 | 0.56 | – | |||||||||||||
Additional information regarding stock options, all of which were held by a related party, as of October 31, 2014, is as follows: | |||||||||||||||||
Number of Warrants | Exercise Price $ | Grant Date | Expiry Date | ||||||||||||||
3,800,000 | 0.005 | 30-Jul-10 | 30-Jul-15 |
Related_Party_Transactions
Related Party Transactions | 9 Months Ended |
Oct. 31, 2014 | |
Notes to Financial Statements | |
Related Party Transactions | As at October 31, 2014, the Company owed $182,614 (January 31, 2014 - $151,384) to the Chief Executive Officer of the Company, which is unsecured, non-interest bearing and due on demand. |
During the nine months ended October 31, 2014, the Company’s director performed services valued at $3,000 which have been recorded as a contribution to capital. |
Fair_Value_Measurements
Fair Value Measurements | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Notes to Financial Statements | |||||||||||||||||
Fair Value Measurements | The Company’s financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, amounts due to related parties, loans payable, convertible debentures and derivative liability. The Company uses the Black-Sholes model to calculate the fair value of the derivative liability. | ||||||||||||||||
Fair Value Measurements Using | |||||||||||||||||
Description | Total Fair | Quoted Prices in Active Markets | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||
Value at | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
31-Oct-14 | |||||||||||||||||
Derivative liabilities | $ | 150,472 | $ | - | $ | 150,472 | $ | - | |||||||||
Fair Value Measurements Using | |||||||||||||||||
Description | Total Fair | Quoted Prices in Active Markets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable | |||||||||||||
Value at | Inputs | ||||||||||||||||
31-Jan-14 | (Level 3) | ||||||||||||||||
Derivative liabilities | $ | 228,765 | $ | - | $ | 228,765 | $ | - |
Subsequent_Events
Subsequent Events | 9 Months Ended |
Oct. 31, 2014 | |
Notes to Financial Statements | |
Subsequent Events | The Company has evaluated subsequent events through the date of issuance of the financial statements, and did not have any material recognizable subsequent events. |
Significant_Accounting_Policie1
Significant Accounting Policies (Policies) | 9 Months Ended | |
Oct. 31, 2014 | ||
Significant Accounting Policies Policies | ||
Basis of Presentation | The financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in Canadian dollars. The Company’s fiscal year-end is January 31. | |
Use of Estimates | The financial statements and the related notes of the Company are prepared in accordance with generally accepted evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, valuation of convertible debentures, assumptions used to determine the fair values of stock-based compensation and derivative liabilities, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | |
Interim Financial Statements | These interim unaudited financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. | |
Cash and Cash Equivalents | The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at October 31 and January 31, 2014, the Company had no cash equivalents. | |
Property and Equipment | Property and equipment is comprised of office equipment and is recorded at cost. The Company amortizes the cost of equipment on a straight-line basis over their estimated useful life of five years. | |
Long-lived Assets | In accordance with ASC 360, “Property, Plant and Equipment”, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. | |
Stock-Based Compensation | The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock-Based Compensation, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. | |
Derivative Financial Instruments | Derivative financial instruments that are not classified as equity and are not used in hedging relationships are measured at fair value. Subsequent changes to fair value are recorded in the statement of operations. | |
Loss Per Share | The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2014, the Company has 4,599,844 (January 31, 2014 – 27,142,888) potentially dilutive shares. | |
Comprehensive Loss | ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at October 31 and January 31, 2014, the Company had no items representing comprehensive income or loss. | |
Research and Development Costs | Research costs are expensed in the period that they are incurred. | |
Financial Instruments and Fair Value Measures | ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: | |
Level 1 | ||
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. | ||
Level 2 | ||
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. | ||
Level 3 | ||
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. | ||
Foreign Currency Translation | The Company’s functional currency and its reporting currency is the Canadian dollar and foreign currency transactions are primarily undertaken in United States dollars. Monetary assets and liabilities are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Expenses are translated at average rates for the period. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. | |
Recent Accounting Pronouncements | In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development or exploration stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of October 31, 2014. | |
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. | ||
Comparative Figures | During the period, the Company determined that certain transactions affecting stockholders’ equity had inadvertently been recorded using a par value of $0.001 in the fiscal year ended January 31, 2014. | |
The Company has determined that its previously filed Form 10-K included a misclassification of $33,000 related to equity. After taking the reclassification into account, the balances of common shares and additional paid-in capital as of January 31, 2014, are $1,184,148 and $754,586, respectively. |
Property_and_Equipment_Tables
Property and Equipment (Tables) | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Property And Equipment Tables | |||||||||||||||||
Property and Equipment | Cost | Accumulated amortization | October 31, 2014 Net carrying value | January 31, 2014 Net carrying value | |||||||||||||
$ | $ | $ | $ | ||||||||||||||
Office furniture and equipment | 2,276 | 1,745 | 531 | 872 |
Derivative_Liabilities_Tables
Derivative Liabilities (Tables) | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Derivative Liabilities Tables | |||||||||||||||||
Schedule of Derivative Liabilities at Fair Value | 31-Oct-14 | 31-Jan-14 | |||||||||||||||
$ | $ | ||||||||||||||||
(unaudited) | |||||||||||||||||
December 2010 convertible debenture | 52,698 | 81,848 | |||||||||||||||
February 2011 convertible debenture | 28,376 | 44,072 | |||||||||||||||
Default penalty on convertible debentures | 47,697 | 74,080 | |||||||||||||||
75,000 warrants expiring on July 4, 2013 | – | – | |||||||||||||||
3,800,000 warrants expiring on July 30, 2015 | 21,702 | 28,765 | |||||||||||||||
150,473 | 228,765 | ||||||||||||||||
Schedule of Interest Rate Derivatives | Expected | Risk-free | Expected | Expected Life | |||||||||||||
Volatility | Interest Rate | Dividend Yield | (in years) | ||||||||||||||
As at issuance date: | |||||||||||||||||
December 2010 convertible debenture | 125 | % | 1.19 | % | 0 | % | 0.75 | ||||||||||
February 2011 convertible debenture | 125 | % | 1.27 | % | 0 | % | 0.75 | ||||||||||
Default penalty on convertible debenture | 125 | % | 0.08 | % | 0 | % | 0.5 | ||||||||||
75,000 warrants expiring on July 4, 2013 | 125 | % | 0.3 | % | 0 | % | 2 | ||||||||||
3,800,000 warrants expiring on July 30, 2015 | 125 | % | 1.26 | % | 0 | % | 4.5 | ||||||||||
As at October 31, 2014: | |||||||||||||||||
December 2010 convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
February 2011 convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
Default penalty on convertible debenture | 285 | % | 0.01 | % | 0 | % | 0.25 | ||||||||||
3,800,000 warrants expiring on July 30, 2015 | 240 | % | 0.08 | % | 0 | % | 0.75 |
Share_Purchase_Warrants_Tables
Share Purchase Warrants (Tables) | 9 Months Ended | ||||||||||
Oct. 31, 2014 | |||||||||||
Share Purchase Warrants Tables | |||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights | Number of Warrants | Weighted Average Exercise Price (US$) | |||||||||
Balance, January 31, 2013 | 3,875,000 | 0.01 | |||||||||
Expired | (75,000 | ) | 0.15 | ||||||||
Balance, October 31 and January 31, 2014 | 3,800,000 | 0.01 | |||||||||
Schedule of Purchase Price Allocation | Number of Warrants | Exercise Price $ | Grant Date | Expiry Date | |||||||
3,800,000 | 0.005 | 30-Jul-10 | 30-Jul-15 |
Stock_Options_Tables
Stock Options (Tables) | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Stock Options Tables | |||||||||||||||||
Schedule of Options Indexed to Issuer's Equity | Number of Options | Weighted Average Exercise Price(US$) | Weighted Average Remaining Contractual Life (years) | Aggregate Intrinsic Value (US$) | |||||||||||||
Outstanding and exercisable, January 31, 2013 | 800,000 | 0.005 | 2.3 | – | |||||||||||||
Outstanding and exercisable, January 31, 2014 | 800,000 | 0.005 | 1.3 | – | |||||||||||||
Outstanding and exercisable, October 31, 2014 | 800,000 | 0.005 | 0.56 | – | |||||||||||||
Schedule of Stock Options Roll Forward | Number of | Exercise Price | Expiry Date | ||||||||||||||
Options | $ | ||||||||||||||||
800,000 | 0.005 | May 25, 2015 |
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 9 Months Ended | ||||||||||||||||
Oct. 31, 2014 | |||||||||||||||||
Fair Value Measurements Tables | |||||||||||||||||
Fair Value Measurement Table Text Block | The Company’s financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, amounts due to related parties, loans payable, convertible debentures and derivative liability. The Company uses the Black-Sholes model to calculate the fair value of the derivative liability. | ||||||||||||||||
Fair Value Measurements Using | |||||||||||||||||
Description | Total Fair | Quoted Prices in Active Markets | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||
Value at | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||
31-Oct-14 | |||||||||||||||||
Derivative liabilities | $ | 150,472 | $ | - | $ | 150,472 | $ | - | |||||||||
Fair Value Measurements Using | |||||||||||||||||
Description | Total Fair | Quoted Prices in Active Markets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable | |||||||||||||
Value at | Inputs | ||||||||||||||||
31-Jan-14 | (Level 3) | ||||||||||||||||
Derivative liabilities | $ | 228,765 | $ | - | $ | 228,765 | $ | - |
Nature_of_Operations_and_Conti1
Nature of Operations and Continuance of Business (Details Narrative) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
Nature Of Operations And Continuance Of Business Details Narrative | ||
Working capital deficit | 771,461 | |
Accumulated deficit | -3,027,664 | -2,914,247 |
Significant_Accounting_Policie2
Significant Accounting Policies (Details Narrative) (CAD) | 9 Months Ended | 12 Months Ended |
Oct. 31, 2014 | Jan. 31, 2014 | |
Significant Accounting Policies Details Narrative | ||
Potentially dilutive shares | 4,599,844 | 27,142,888 |
Additional paid-in capital | 757,586 | 754,586 |
Common stock balance outstanding | 1,151,148 |
Property_and_Equipment_Details
Property and Equipment (Details) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
October 31, 2014 Net carrying value | 531 | 872 |
Office furniture and equipment [Member] | ||
Cost | 2,276 | |
Accumulated amortization | 1,745 | |
October 31, 2014 Net carrying value | 531 | |
January 31, 2014 Net carrying value | 872 |
Convertible_Debentures_Details
Convertible Debentures (Details Narrative) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
On December 17, 2010 [Member] | ||
Carrying value convertible debenture | 22,542 | 22,276 |
Accrued default penalty | 11,271 | 11,138 |
Accrued interest | 1,572 | 1,553 |
Derivative Liability | 81,684 | 126,868 |
On February 23, 2011 [Member] | ||
Carrying value convertible debenture | 45,084 | 44,552 |
Accrued default penalty | 22,542 | 22,276 |
Accrued interest | 4,400 | 4,348 |
Derivative Liability | 47,087 | 73,133 |
On July 4, 2011 [Member] | ||
Carrying value convertible debenture | 112,710 | 111,380 |
Accrued interest | 78,706 | 57,783 |
On April 26, 2013 [Member] | ||
Carrying value convertible debenture | 16,907 | 8,572 |
Accrued interest | 6,147 | 2,974 |
Derivative_Liabilities_Details
Derivative Liabilities (Details) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
Derivative liabilities | 150,473 | 228,765 |
December 2010 convertible debenture | ||
Derivative liabilities | 52,698 | 81,848 |
Default Penalty On Convertible Debentures | ||
Derivative liabilities | 47,697 | 74,080 |
75,000 warrants expiring on July 4, 2013 | ||
Derivative liabilities | ||
3,800,000 Warrants Expiring on July 30, 2015 | ||
Derivative liabilities | 21,702 | 28,765 |
February 2011 convertible debenture | ||
Derivative liabilities | 28,376 | 44,072 |
Derivative_Liabilities_Details1
Derivative Liabilities (Details 1) | 12 Months Ended | 9 Months Ended |
Jan. 31, 2014 | Oct. 31, 2014 | |
As at issuance date- December 2010 convertible debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 125.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 1.19% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 9 months | |
As At Issuance Date February 2011 Convertible Debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 125.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 1.27% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 9 months | |
As at issuance date- default penalty on covertible debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 125.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.08% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 6 months | |
As at issuance date 75,000 Warrants Expiring on July 4, 2013 | ||
Fair Value Assumptions, Expected Volatility Rate | 125.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.30% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 2 years | |
As at issuance date 3,800,000 Warrants Expiring on July 30, 2015 | ||
Fair Value Assumptions, Expected Volatility Rate | 125.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 1.26% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 4 years 6 months | |
As at October 31, 2014 Convertible Debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 285.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.01% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 3 months | |
As at October 31, 2014 - February 2011 convertible debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 285.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.01% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 3 years | |
As at October 31, 2014:- default penalty on covertible debenture | ||
Fair Value Assumptions, Expected Volatility Rate | 285.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.01% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 3 months | |
As at October 31, 2014:- 3,800,000 warrants expiring on July 30, 2015 | ||
Fair Value Assumptions, Expected Volatility Rate | 240.00% | |
Fair Value Assumptions, Risk Free Interest Rate | 0.08% | |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 9 months |
Common_Shares_Details_Narrativ
Common Shares (Details Narrative) (CAD) | 3 Months Ended | 9 Months Ended | ||
Oct. 31, 2014 | Oct. 31, 2013 | Oct. 31, 2014 | Oct. 31, 2013 | |
Common Shares Details Narrative | ||||
Financing costs | -90,000 | -63,000 | ||
Default costs |
Share_Purchase_Warrants_Detail
Share Purchase Warrants (Details) (USD $) | 12 Months Ended | |
Jan. 31, 2014 | Oct. 31, 2014 | |
Share Purchase Warrants Details | ||
Number, Beginning Balance | 3,875,000 | 3,800,000 |
Weighted Average Exercise Price, Beginning Balance | $0.01 | |
Expirations in Period | -75,000 | |
Weighted Average Exercise Price | $0.15 | |
Number, Ending Balance | 3,800,000 | 3,800,000 |
Weighted Average Exercise Price, Ending Balance | $0.01 |
Share_Purchase_Warrants_Detail1
Share Purchase Warrants (Details 1) (USD $) | 9 Months Ended | ||
Oct. 31, 2014 | Jan. 31, 2014 | Jan. 31, 2013 | |
Share purchase warrants outstanding, number | 3,800,000 | 3,800,000 | 3,875,000 |
Share purchase warrants outstanding, grant price | 30-Jul-10 | ||
Share purchase warrants outstanding, expiry date | 30-Jul-15 | ||
Warrant [Member] | July 30, 2015 | |||
Share purchase warrants outstanding, number | 3,800,000 |
Stock_Options_Details
Stock Options (Details) (USD $) | 9 Months Ended | 12 Months Ended | |
Oct. 31, 2014 | Jan. 31, 2014 | Jan. 31, 2013 | |
Stock Options Details | |||
Number of Outstanding Options | 800,000 | 800,000 | 800,000 |
Weighted Average Exercise Price | $0.01 | $0.01 | $0.01 |
Weighted Average Remaining Contractual Term | 6 months 22 days | 1 year 3 months 18 days | 2 years 3 months 18 days |
Aggregate Intrinsic Value |
Stock_Options_Details_1
Stock Options (Details 1) (USD $) | Oct. 31, 2014 | Jan. 31, 2014 | Jan. 31, 2013 | Apr. 30, 2014 |
Share purchase warrants outstanding, number | 3,800,000 | 3,800,000 | 3,875,000 | |
Stock Option [Member] | May 25, 2015 | ||||
Share purchase warrants outstanding, number | 800,000 | |||
Share purchase warrants outstanding exercise price | $0.01 |
Related_Party_Transactions_Det
Related Party Transactions (Details Narrative) (CAD) | 9 Months Ended | |
Oct. 31, 2014 | Jan. 31, 2014 | |
Contribution capital | 3,000 | |
Chief Executive Officer [Member] | ||
Company owed | 182,614 | 151,384 |
Fair_Value_Measurements_Detail
Fair Value Measurements (Details) (CAD) | Oct. 31, 2014 | Jan. 31, 2014 |
Derivative liabilities | 150,472 | 228,765 |
Quoted Prices in Active Markets Level 1 [Member] | ||
Derivative liabilities | ||
Significant Other Observable Inputs Level 2 [Member] | ||
Derivative liabilities | 150,472 | 228,765 |
Significant Unobservable Inputs Level 3 [Member] | ||
Derivative liabilities |
Uncategorized_Items
Uncategorized Items | |
[us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice] | 0.005 |